A study to test how well different doses of BI 3810477 are tolerated by healthy men

2024-513419-28-00 Protocol 1530-0001 Human pharmacology (Phase I) - First administration to humans Ended

Start 22 Oct 2024 · End 12 Jun 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol 1530-0001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 80
Countries 1
Sites 1

Healthy volunteer trial

Key facts

Sponsor
Boehringer Ingelheim International GmbH
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Diseases [C] - Respiratory Tract Diseases [C08]
Trial duration
22 Oct 2024 → 12 Jun 2025
Decision date (initial)
2024-10-14
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
No

External identifiers

EU CT number
2024-513419-28-00
WHO UTN
U1111-1306-7752

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy volunteer trial

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Boehringer Ingelheim International GmbH

Sponsor organisation
Boehringer Ingelheim International GmbH
Address
Binger Strasse 173
City
Ingelheim Am Rhein
Postcode
55216
Country
Germany

Scientific contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Public contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ended 80 1
Rest of world 0

Investigational sites

Belgium

1 site · Ended
SGS Belgium
Clinical Pharmacology Unit, Drie Eikenstraat 655, 2650, Edegem

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2024-10-22 2025-06-12 2024-10-30 2025-05-04

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-31 Belgium Acceptable with conditions
2024-10-14
2024-10-14
2 SUBSTANTIAL MODIFICATION SM-1 2024-12-13 Belgium Acceptable
2025-01-20
2025-01-23